ATE97498T1 - Verbesserungen an wachstumsfaktoren. - Google Patents

Verbesserungen an wachstumsfaktoren.

Info

Publication number
ATE97498T1
ATE97498T1 AT85900716T AT85900716T ATE97498T1 AT E97498 T1 ATE97498 T1 AT E97498T1 AT 85900716 T AT85900716 T AT 85900716T AT 85900716 T AT85900716 T AT 85900716T AT E97498 T1 ATE97498 T1 AT E97498T1
Authority
AT
Austria
Prior art keywords
egf receptor
growth factors
neoplastic
assaying
conjugates
Prior art date
Application number
AT85900716T
Other languages
English (en)
Inventor
Michael Waterfield
Fields Inn
J Schlessinger
Axel Ullrich
Original Assignee
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848402379A external-priority patent/GB8402379D0/en
Priority claimed from GB858500538A external-priority patent/GB8500538D0/en
Application filed by Imp Cancer Res Tech filed Critical Imp Cancer Res Tech
Application granted granted Critical
Publication of ATE97498T1 publication Critical patent/ATE97498T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/027—Making masks on semiconductor bodies for further photolithographic processing not provided for in group H01L21/18 or H01L21/34
    • H01L21/0271—Making masks on semiconductor bodies for further photolithographic processing not provided for in group H01L21/18 or H01L21/34 comprising organic layers
    • H01L21/0273—Making masks on semiconductor bodies for further photolithographic processing not provided for in group H01L21/18 or H01L21/34 comprising organic layers characterised by the treatment of photoresist layers
    • H01L21/0274—Photolithographic processes
    • H01L21/0276—Photolithographic processes using an anti-reflective coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Power Engineering (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Toxicology (AREA)
  • Manufacturing & Machinery (AREA)
AT85900716T 1984-01-30 1985-01-30 Verbesserungen an wachstumsfaktoren. ATE97498T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB848402379A GB8402379D0 (en) 1984-01-30 1984-01-30 Polypeptides
GB858500538A GB8500538D0 (en) 1985-01-09 1985-01-09 Oligonucleotide probes
PCT/GB1985/000045 WO1985003357A1 (en) 1984-01-30 1985-01-30 Improvements relating to growth factors
EP85900716A EP0171407B1 (de) 1984-01-30 1985-01-30 Verbesserungen an wachstumsfaktoren

Publications (1)

Publication Number Publication Date
ATE97498T1 true ATE97498T1 (de) 1993-12-15

Family

ID=26287248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85900716T ATE97498T1 (de) 1984-01-30 1985-01-30 Verbesserungen an wachstumsfaktoren.

Country Status (7)

Country Link
US (1) US4933294A (de)
EP (2) EP0171407B1 (de)
AT (1) ATE97498T1 (de)
AU (1) AU3934085A (de)
DE (1) DE3587657D1 (de)
IL (1) IL74201A0 (de)
WO (1) WO1985003357A1 (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
US5100774A (en) * 1988-04-22 1992-03-31 The Wistar Institute Of Anatomy & Biology Methods for detecting growth factor receptor expression
US5210039A (en) * 1989-02-09 1993-05-11 Eastman Kodak Company Wash composition, test kit and their use to determine a herpes simplex viral antigen
US7282345B1 (en) * 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
US5981725A (en) * 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
JP3208427B2 (ja) * 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
AU7774391A (en) * 1990-04-20 1991-11-11 Ludwig Institute For Cancer Research Aberrant, epidermal growth factor receptor dna, rna and protein forms and method
US5874528A (en) * 1990-05-25 1999-02-23 Georgetown University Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2 receptor
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5218090A (en) * 1990-06-12 1993-06-08 Warner-Lambert Company EGF receptor truncates
WO1992006220A1 (en) * 1990-10-05 1992-04-16 President And Fellows Of Harvard College Detection and isolation of ligands
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
AU2178292A (en) * 1991-06-03 1993-01-08 Triton Diagnostics, Inc. Epidermal growth factor receptor ectodomain
US5344760A (en) * 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
WO1993014781A1 (en) * 1992-01-24 1993-08-05 The Regents Of The University Of California Novel peptides and method for altering the activity of allosteric proteins
AU676476B2 (en) * 1992-04-29 1997-03-13 Georgetown University Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2-receptor
ATE194658T1 (de) * 1992-09-03 2000-07-15 Univ California Das dorsalgewebe beeinflussender faktor
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
US7285532B2 (en) * 1992-09-03 2007-10-23 Regeneron Pharmaceuticals, Inc. Therapeutic method for treating bone formation diseases
AU5136093A (en) * 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
AU5548694A (en) * 1992-11-06 1994-06-08 Warner-Lambert Company Peptide inhibitors of tyrosine kinases and therapeutic uses thereof
WO1995006656A1 (en) * 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US7052692B1 (en) 1997-09-02 2006-05-30 Advanced Research & Technology Institute Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
GB9821170D0 (en) * 1998-09-30 1998-11-25 Univ Ulster Marker
ES2357406T3 (es) * 1998-10-09 2011-04-26 Vegenics Limited Flt4 (VEGFR-3) COMO DIANA PARA LA OBTENCIÓN DE IMÁGENES DE TUMORES Y TERAPIA ANTITUMORAL.
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
BRPI0012196B8 (pt) 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
WO2001000245A2 (en) 1999-06-25 2001-01-04 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US7732157B1 (en) 1999-09-30 2010-06-08 Tumor Biology Investment Group Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
AU2002248372B8 (en) * 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (de) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Spezifische bindungsproteine und ihre verwendung
ES2372321T3 (es) 2001-06-20 2012-01-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
JP2005508887A (ja) * 2001-08-03 2005-04-07 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション Ｅｇｆ受容体の結晶構造に基づいたスクリーニング方法
EP2151244A1 (de) 2001-09-18 2010-02-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
MXPA04006554A (es) 2002-01-02 2005-03-31 Genentech Inc Composiciones y metodos para diagnostico y tratamiento de tumor.
WO2003087131A2 (en) 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
EP1571968A4 (de) 2002-04-16 2007-10-17 Genentech Inc Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
DK1585966T3 (da) 2002-07-15 2012-02-20 Hoffmann La Roche Behandling af cancer med anti-ErbB2-antistoffet rhuMab 2C4
AU2004265226A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
US20060068444A1 (en) * 2004-03-19 2006-03-30 Zelos Therapeutics, Inc Compositions and methods for detecting cyclic analogs of hPTH
BRPI0508761A (pt) * 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP1753463A2 (de) 2004-06-01 2007-02-21 Genentech, Inc. Antikörper-wirkstoff-konjugate und verfahren
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7964195B2 (en) 2005-01-07 2011-06-21 Diadexus, Inc. Ovr110 antibody compositions and methods of use
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
RS53128B (en) 2005-02-23 2014-06-30 Genentech Inc. Extending the time of disease progression or survival in patients with ovarian cancers using PERTUZUMAB
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
AU2007319757B2 (en) 2006-03-21 2013-09-19 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
EP2007428A2 (de) 2006-04-05 2008-12-31 Genentech, Inc. Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
EP2044115A2 (de) * 2006-06-12 2009-04-08 Receptor Biologix, Inc. Für die oberflächenrezeptoren von pan-zellen spezifische therapeutika
PL2845866T3 (pl) 2006-10-27 2017-10-31 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowanie
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
EP2436781B1 (de) 2007-02-22 2015-10-07 Genentech, Inc. Verfahren für den Nachweis von entzündlicher Darmerkrankung
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
RU2010119556A (ru) * 2007-10-16 2011-11-27 Симфоген А/С (Dk) Композиции, содержащие оптимизированные мультимеры her1 и her3, и способы их применения
US20100330592A1 (en) * 2008-01-29 2010-12-30 Key Marc E Method for detecting truncated molecules
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
HUE029869T2 (en) 2008-01-31 2017-04-28 Genentech Inc Anti-CD79B antibodies and immunoconjugates, as well as application procedures
SG10201609416XA (en) 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TWI537383B (zh) 2009-11-30 2016-06-11 建南德克公司 診斷及治療腫瘤之組合物及方法
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2011130580A1 (en) 2010-04-15 2011-10-20 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA2795972A1 (en) 2010-06-03 2011-12-08 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
UY33498A (es) 2010-07-09 2013-01-03 Sanofi Aventis Combinaciones de inhibidores de quinasas para el tratamiento de cancer
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
CN104067128A (zh) 2011-12-05 2014-09-24 霍夫曼-拉罗奇有限公司 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
KR20150024342A (ko) 2012-06-26 2015-03-06 에프. 호프만-라 로슈 아게 유방암을 치료하기 위한 베바시주맙 조합 요법에 대한 혈장 바이오마커
PE20151769A1 (es) 2013-04-16 2015-12-11 Genentech Inc Variantes de pertuzumab y su evalaucion
DK3148581T3 (da) 2014-05-30 2020-01-13 Henlix Biotech Co Ltd Anti-epidermal vækstfaktorreceptor (egfr)-antistoffer
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
CN107614020A (zh) 2015-03-18 2018-01-19 免疫生化公司 靶向细胞内肿瘤相关抗原的用于治疗癌症的缀合物
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
EP4339615A3 (de) 2016-09-16 2024-05-22 Shanghai Henlius Biotech, Inc. Anti-pd-1-antikörper
WO2018125589A1 (en) 2016-12-28 2018-07-05 Genentech, Inc. Treatment of advanced her2 expressing cancer
SG10202011384XA (en) 2017-01-17 2021-01-28 Genentech Inc Subcutaneous her2 antibody formulations
EP3589661B1 (de) 2017-03-02 2023-11-01 Genentech, Inc. Adjuvansbehandlung von her2-positivem brustkrebs
MX2020009514A (es) 2018-03-14 2020-12-07 Beijing Xuanyi Pharmasciences Co Ltd Anticuerpos anti-claudina 18.2 (cldn18.2).
TWI811335B (zh) 2018-04-13 2023-08-11 美商建南德克公司 穩定抗ｃｄ７９ｂ免疫結合物調配物
PL3853220T3 (pl) 2018-09-18 2024-09-02 F. Hoffmann-La Roche Ag Pochodne chinazoliny jako leki przeciwnowotworowe
US20210032285A1 (en) * 2019-03-11 2021-02-04 Cell Idx, Inc. Methods, compositions, and kits for trapping modified biomolecules
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021168074A1 (en) 2020-02-18 2021-08-26 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
EP4182688A1 (de) 2020-07-14 2023-05-24 F. Hoffmann-La Roche AG Tests für kombinationen mit festgelegter dosis
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
IL306067A (en) 2021-03-26 2023-11-01 Theseus Pharmaceuticals Inc Macrocyclic EGFR inhibitors for cancer treatment
WO2022229846A1 (en) 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
CA3218374A1 (en) 2021-05-11 2022-11-17 Wei-Sheng Huang Macrocyclic compounds and uses thereof
WO2023109900A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
EP4448579A1 (de) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40-antikörper und verfahren zur verwendung
AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof

Also Published As

Publication number Publication date
DE3587657D1 (de) 1993-12-23
AU3934085A (en) 1985-08-09
US4933294A (en) 1990-06-12
WO1985003357A1 (en) 1985-08-01
IL74201A0 (en) 1985-04-30
EP0171407B1 (de) 1993-11-18
EP0171407A1 (de) 1986-02-19
EP0491675A1 (de) 1992-06-24

Similar Documents

Publication Publication Date Title
ATE97498T1 (de) Verbesserungen an wachstumsfaktoren.
De Larco et al. Sarcoma growth factor (SGF): specific binding to epidermal growth factor (EGF) membrane receptors
Pruss et al. Mitogens for glial cells: a comparison of the response of cultured astrocytes, oligodendrocytes and Schwann cells
GEP20022681B (en) Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
ATE249476T1 (de) Cyclin d1 und seine cdna
ATE110773T1 (de) Verfahren zur züchtung rekombinanter zellen.
NO995458D0 (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
DE68905633D1 (de) Markierer der t-zelle aktivierung.
ATE498013T1 (de) Für zellzyklusproteine kodierende nukleinsäure und deren verwendung
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
Yashiro et al. Insulin-like growth factor-II (IGF-II)/mannose-6-phosphate receptors are increased in primary human thyroid neoplasms
ATE331794T1 (de) Humane prostacyclinsynthase
WO2003106648A3 (en) COMPOSITIONS AND METHODS RELATED TO BREAST SPECIFIC GENES AND PROTEINS
AU693800B2 (en) Diagnostic agents for osteoporosis
Mizobe et al. Induction of a specific protein by oestradiol in rat pineals in culture
AU2020350442A1 (en) Endothelial and smooth muscle like tissue produced from urine cells and uses related thereto
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
Roch et al. Differences in polyamine availability and insertion into fibronectins released from normal and transformed cells
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004052290A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
Schofield et al. Synthesis of procollagen by matrix-free cells from embryonic-chick arteries